Program Highlights
- More than 40 percent of U.S. patients with cancer are estimated to be eligible for checkpoint inhibitors, but less than 13 percent respond to the treatment
- We are targeting TGF-ß activating integrins such as avß8 that are upregulated in certain tumors with the goal of removing the anti-inflammatory effect and, ultimately, sensitizing tumors to checkpoint inhibitors
- We have shown in an EMT6 anti-PD-1 resistant tumor mouse model that our small molecule inhibitors of αvβ8-mediated TGF-ß activation are able to sensitize tumors to anti-PD-1 therapy and extend survival
Development Status
- This program is currently in preclinical development